keytruda gardasil upward revis
merck report robust result show excel growth keytruda
gardasil merck sale line expect
achiev strong growth keytruda gardasil
comfort offset declin zepati zostavax
guidanc full year narrow mid-point unchang
earn beat margin expect improv non-gaap
ep beat expect merck rais full-year non-gaap
ep guidanc merck deliv profit
sale growth investor call ceo ken frazier confid
margin improv lie ahead
keytruda win immuno-oncolog io forecast rais keytruda
continu deliv excel efficaci data rang cancer type
latest news suggest power benefit renal cancer
revisit assumpt keytruda rais sale forecast
except sale outsid us grow
compani believ ex-u growth continu mani market chang
guidelin adopt major vaccin programm sex
significantli rais gardasil sale forecast
non-gaap earn rais net effect rais
sale forecast keytruda gardasil keep cost
control lift non-gaap ep sit ahead
current consensu
dcf jump price target reset result forecast
chang dcf climb reset price target
robust outlook larg price despit bullish
forecast share perform strongli year
year date result believ upsid enough
upgrad buy stage
chang made note
hold chang
perform rel
merck co global biopharmaceut
compani base us
profit loss summari
growth margin
merck benefit major growth driver immuno-
oncolog io keytruda drug drive sale
margin higher medium term howev earli next decad
merck manag substanti patent expiri januvia
could dramat slow growth
forecast balanc gener eros new growth
driver result net sale growth significantli differ
sector around per annum
expect sale mix swing toward profit
special product help merck continu deliv
balanc think merck set deliv earn growth close
peer group medium term price-to-earnings
slight discount peer leav share
valuat price target dcf-deriv
chang net debt
average cost debt
risk invest thesi
merck sever interest phase project includ gefapix
chronic cough could emerg futur blockbust
io field evolv quickli merck excel keytruda
emerg near-term winner forecast sale
keytruda howev still fast-evolv landscap
new data merck competitor could significantli help
proquad m-m-r ii varivax
profit loss account
sale
market administr
 revenu
research develop
 revenu
equiti incom affili
incom tax
incom tax
incom tax
incom tax
attribut non control interest
net incom attribut merck co inc
net incom attribut merck co inc
net incom attribut merck co inc
net incom attribut merck co inc
cash equival
defer incom tax current asset
loan payabl current portion long term debt
accru current liabil
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
depreci amort
net provid oper activ
net provid oper activ
net provid oper activ
net provid oper activ
acquisit busi net cash acquir
net use invest activ
net use invest activ
net use invest activ
net use invest activ
net chang short-term borrow
payment debt
proce issuanc debt
purchas treasuri stock
dividend paid stockhold
proce exercis stock option
net use financ activ
net use financ activ
net use financ activ
net use financ activ
effect fx cash cash equival
increas cash cash equival
cash equival begin year
cash equival end year
cash equival end year
cash equival end year
cash equival end year
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
